<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04586829</url>
  </required_header>
  <id_info>
    <org_study_id>UIE-3506-20-21-1</org_study_id>
    <nct_id>NCT04586829</nct_id>
  </id_info>
  <brief_title>The Effect of Two Dietary Interventions on the Symptomatic Control of People Living With Anxiety Disorders.</brief_title>
  <official_title>The Effect of Two Dietary Interventions on the Symptomatic Control of People Living With Anxiety Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomised controlled trial will evaluate the effect of a ketogenic diet vs a&#xD;
      conventional diet on the symptoms of patients living with anxiety disorders using a validate&#xD;
      self-reported inventory.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been theorized that ketogenic diet could improve symptom control in patients living&#xD;
      with anxiety disorders. Animal models support this hypothesis but to this date, studies in&#xD;
      humans are lacking.&#xD;
&#xD;
      The investigators will randomise patients with a confirmed diagnosis of anxiety disorders to&#xD;
      follow a ketogenic diet (&lt;50 grs of carbohydrate per day) or a conventional diet (50%&#xD;
      carbohydrate, 30% lipids, 20% protein) for one month.&#xD;
&#xD;
      Symptom control will be assessed weekly using Beck's inventory for Anxiety. Diet adherence&#xD;
      will be measured using standardised food frequency logs and acetoacetate urine strips.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptom control</measure>
    <time_frame>One month</time_frame>
    <description>Total points in Beck's Inventory for Anxiety. Scores range between 0 to 63 and higher numbers mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective self perceived control</measure>
    <time_frame>One month</time_frame>
    <description>Self-assessed and reported symptom ranging between 0 - 100. Higher numbers mean a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Anxiety Disorders</condition>
  <arm_group>
    <arm_group_label>Conventional diet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional diet. (50% carbohydrate, 30% lipids, 20% protein). Current dietary recommendations from official guidelines will be reinforced.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketogenic diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tailored ketogenic diet. Participants will be allowed to chose their meals as long as they consume less than 50gr of carbohydrates per day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Diet</intervention_name>
    <description>&lt;50 grams of total carbohydrates per day. Monosaturated fats consumption will be encouraged over saturated fats.</description>
    <arm_group_label>Conventional diet</arm_group_label>
    <arm_group_label>Ketogenic diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a confirmed diagnosis of Anxiety Disorder by Psychiatrist.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with the diagnosis of drug abuse, cognitive impairment or dementia,&#xD;
             porphyria, carnitine translocase deficiency and carnitine palmitoyl transferase&#xD;
             deficiency.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian Soto, MD,DPhil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biomedical Sciences Researcher</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>INCMNSZ</name>
      <address>
        <city>Mexico City</city>
        <state>Cdmx</state>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Ari C, Kovács Z, Juhasz G, Murdun C, Goldhagen CR, Koutnik AP, Poff AM, Kesl SL, D'Agostino DP. Corrigendum: Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats. Front Mol Neurosci. 2017 Feb 13;10:36. doi: 10.3389/fnmol.2017.00036. eCollection 2017.</citation>
    <PMID>28210213</PMID>
  </reference>
  <reference>
    <citation>Fydrich, T., Dowdall, D. and Chambless, D. L. (1992) 'Reliability and validity of the beck anxiety inventory', Journal of Anxiety Disorders, 6(1), pp. 55-61. doi: 10.1016/0887-6185(92)90026-4.</citation>
  </reference>
  <reference>
    <citation>Kashiwaya Y, Bergman C, Lee JH, Wan R, King MT, Mughal MR, Okun E, Clarke K, Mattson MP, Veech RL. A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease. Neurobiol Aging. 2013 Jun;34(6):1530-9. doi: 10.1016/j.neurobiolaging.2012.11.023. Epub 2012 Dec 29.</citation>
    <PMID>23276384</PMID>
  </reference>
  <reference>
    <citation>Kovács Z, D'Agostino DP, Diamond D, Kindy MS, Rogers C, Ari C. Therapeutic Potential of Exogenous Ketone Supplement Induced Ketosis in the Treatment of Psychiatric Disorders: Review of Current Literature. Front Psychiatry. 2019 May 23;10:363. doi: 10.3389/fpsyt.2019.00363. eCollection 2019. Review.</citation>
    <PMID>31178772</PMID>
  </reference>
  <reference>
    <citation>Saslow LR, Daubenmier JJ, Moskowitz JT, Kim S, Murphy EJ, Phinney SD, Ploutz-Snyder R, Goldman V, Cox RM, Mason AE, Moran P, Hecht FM. Twelve-month outcomes of a randomized trial of a moderate-carbohydrate versus very low-carbohydrate diet in overweight adults with type 2 diabetes mellitus or prediabetes. Nutr Diabetes. 2017 Dec 21;7(12):304. doi: 10.1038/s41387-017-0006-9.</citation>
    <PMID>29269731</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>October 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</investigator_affiliation>
    <investigator_full_name>Luis Adrian Soto Mota</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Upon request to PI.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>One year after publication</ipd_time_frame>
    <ipd_access_criteria>Send email to adrian.sotom@incmnsz.mx</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

